Jan 01, 2013 - 10:13 am
New chemotherapeutic and biologic agents, which prolong survival in patients with mCRC, present physicians with new challenges. With the availability of these agents, patients may require treatment for longer periods than ever before, which calls into question the optimum sequence and duration of treatment. Recent studies in patients with mCRC have investigated a variety of approaches to treatment, including intermittent chemotherapy , stop-and-go therapy [18, 21, 24, 25], and low-intensity maintenance strategies [20, 21], with the aim of reducing the burden of treatment for patients. The present study is, however, the first study to investigate the role of maintenance with a biological agent alone as part of the treatment regimen.
Read it enjoy, i am not advocating hardcore chemo, but the slective use of appropriate agents may help some, my german onc likes the stop and go and low intensity style and of course directed by chemo sensitivity testing.